Spruance S L
Department of Medicine, School of Medicine, University of Utah, Salt Lake City 84132.
Semin Dermatol. 1992 Sep;11(3):200-6.
Oral-facial herpes simplex virus infection is a common, worldwide affliction on which neither public health procedures, vaccines, nor antiviral chemotherapy have yet to have a significant clinical impact. Careful examination of the pathogenesis and clinical features of this illness could lead to insights and a rationale for new and more effective preventive and therapeutic measures. The resistance of recurrent herpes simplex labialis to antiviral chemotherapy may be caused in part by inoculation of the skin simultaneously at multiple foci, such that only a few cycles of virus replication are needed before there is coalescence of the foci, destruction of the epidermis, and clinical lesion formation. Studies of herpes simplex labialis induced by ultraviolet radiation have suggested that there is a subpopulation of lesions that develop immediately after irradiation and that are refractory to chemotherapy. The difficulty finding a treatment for herpes simplex labialis may in part be methodological. Clinical trial protocols for antiviral drugs should target susceptible lesion subgroups and specific stages of the disease.
口腔面部单纯疱疹病毒感染是一种常见的全球性疾病，公共卫生措施、疫苗及抗病毒化疗对其均未产生显著的临床影响。仔细研究该疾病的发病机制和临床特征可能会为新的、更有效的预防和治疗措施带来启发及理论依据。复发性唇疱疹对抗病毒化疗的耐药性可能部分是由于皮肤在多个病灶同时接种，以至于在病灶融合、表皮破坏和临床病损形成之前，仅需几个病毒复制周期。紫外线辐射诱发唇疱疹的研究表明，有一部分病损在照射后立即出现，且对化疗耐药。唇疱疹治疗困难可能部分在于方法学问题。抗病毒药物的临床试验方案应针对易感病损亚组和疾病的特定阶段。
